Cetuximab 100mg/20mL (5mg/mL) Infusion$130.00
1–9 boxes
$130.00 each
10–24 boxes
8% off
25+ boxes
10% off
Cetuximab 100mg/20mL (5mg/mL) Infusion
SKU GME1375Oncology Care
Product Introduction
Cetuximab 100mg/20mL (5mg/mL) is an EGFR-directed monoclonal antibody for selected head-and-neck and colorectal cancers. In colorectal cancer, tumour RAS testing helps determine whether treatment is appropriate.
How to use
Administer by controlled intravenous infusion with antihistamine premedication and monitoring for reactions. It is not an intravenous bolus. Electrolytes and the skin are monitored through the treatment course.
How it works
Cetuximab binds the extracellular domain of EGFR and blocks growth-factor signalling. It can also help immune cells recognise tumour cells.
Side effects
An acne-like rash, dry skin, nail-fold inflammation, diarrhoea and low magnesium can occur. Severe infusion reactions and lung inflammation are important serious risks.
Important information
Severe allergy can occur during the first infusion. Previous tick bites, red-meat allergy or alpha-gal sensitisation may be relevant. Magnesium, potassium and calcium can remain low after treatment ends.
Uses
- Selected RAS-wild-type metastatic colorectal cancer and squamous-cell head-and-neck cancer regimens.
Benefits
Blocking EGFR can improve control of a susceptible tumour when biomarkers and the treatment setting match.
Does every colorectal cancer respond to an EGFR antibody?
No. RAS mutations can make treatment ineffective, so molecular selection is essential.
Is the acne-like rash ordinary acne?
It is an EGFR-related skin reaction and may need a different skin-care or antibiotic plan from conventional acne.
Why can electrolyte tests continue after the final infusion?
Renal magnesium loss can persist for several weeks, affecting potassium and calcium balance as well.
How should I protect my skin from sunlight during cetuximab treatment?
Limit direct sun exposure and use sunscreen, protective clothing and a hat. Continue this protection for two months after treatment ends because cetuximab-related skin sensitivity can persist.
EGFR: epidermal growth factor receptor. RAS wild-type: no relevant RAS mutation detected. Hypomagnesaemia: low blood magnesium.; AR: Cetuximab 100mg/20mL (5mg/mL) تسريب وريدي; FR: Cetuximab 100mg/20mL (5mg/mL) perfusion intraveineuse; PT: Cetuximab 100mg/20mL (5mg/mL) infusão intravenosa; ES: Cetuximab 100mg/20mL (5mg/mL) perfusión intravenosa; RU: Cetuximab 100mg/20mL (5mg/mL) внутривенная инфузия; ID: Cetuximab 100mg/20mL (5mg/mL) infus intravena; VI: Cetuximab 100mg/20mL (5mg/mL) thuốc truyền tĩnh mạch; MS: Cetuximab 100mg/20mL (5mg/mL) infusi intravena; TL: Cetuximab 100mg/20mL (5mg/mL) pagbubuhos sa ugat; ZH-SG: Cetuximab 100mg/20mL (5mg/mL) 静脉输注